Veale D J, Maple C, Kirk G, McLaren M, Belch J J
University Department of Medicine, Ninewells Hospital, Dundee, Scotland.
Scand J Rheumatol. 1998;27(4):296-9. doi: 10.1080/030097498442415.
The aim of this pilot study was to examine soluble cell adhesion molecules before and after sulphasalazine (SSZ) therapy in active RA. Assessment of RA patients (n = 13) was undertaken before and after 3 months of SSZ. sICAM-1, sVCAM-1, sP- and sE-selectin were measured using an ELISA. The mean (+/-SEM) C-reactive protein (CRP) and sP-selectin levels were significantly reduced from 3.9(0.89) to 2.01(0.53) mg/dl and from 332.8 (48.2) to 116.2 (11.1) respectively, after 3 months of SSZ. The sICAM-1 and sP-selectin levels were significantly higher in RA patients at baseline and a reduction occurred of sICAM-1, sVCAM-1 and sE-selectin levels, however this was not significant. The fall in mean (SEM) sICAM-1, from 345.0 (29.8) to 333.5 (30.2), correlated with the change in CRP (r=0.66; p = 0.018), but the fall in sP-selectin did not. SSZ therapy reduced sP-selectin and sICAM-1 levels in active RA, sICAM-1 correlates with disease activity. SSZ may reduce platelet and/or endothelial activity in RA which may be a useful marker of response, however studies of longer duration and more patients are required.
这项初步研究的目的是检测活动性类风湿关节炎（RA）患者在使用柳氮磺胺吡啶（SSZ）治疗前后的可溶性细胞粘附分子。对13例RA患者在SSZ治疗3个月前后进行了评估。使用酶联免疫吸附测定法（ELISA）检测可溶性细胞间粘附分子-1（sICAM-1）、可溶性血管细胞粘附分子-1（sVCAM-1）、可溶性P-选择素和可溶性E-选择素。SSZ治疗3个月后，平均（±标准误）C反应蛋白（CRP）和可溶性P-选择素水平分别从3.9（0.89）显著降至2.01（0.53）mg/dl和从332.8（48.2）降至116.2（11.1）。RA患者基线时sICAM-1和可溶性P-选择素水平显著更高，sICAM-1、sVCAM-1和可溶性E-选择素水平出现下降，但不显著。可溶性ICAM-1平均水平（标准误）从345.0（29.8）降至333.5（30.2），与CRP变化相关（r = 0.66；p = 0.018），但可溶性P-选择素下降与之无关。SSZ治疗降低了活动性RA患者的可溶性P-选择素和sICAM-1水平，sICAM-1与疾病活动相关。SSZ可能降低RA患者的血小板和/或内皮细胞活性，这可能是反应的有用标志物，然而需要进行更长时间和更多患者的研究。
